Petat A, Dansin E, Calcagno F, Greillier L, Pichon E, Kerjouan M, Mennecier B, Westeel V, Thillays F, Quantin X, Oulkhouir Y, Thiberville L, Ricordel C, Thomas De Montpreville V, Chalabreysse L, Hofman V, Molina T, Fournel P, Bigay Game L, Besse B, Girard N Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. Eur J Cancer. 2022;162. doi:10.1016/j.ejca.2021.11.028
Edelman M, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng C, Bentsion D, Chouaid C, Dechev H, Dowlati A, Fernández Núñez N, Ivashchuk O, Kiladze I, Kortua T, Leighl N, Luft A, Makharadze T, Min Y, Quantin X Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. Lung Cancer. 2022;166. doi:10.1016/j.lungcan.2022.03.003
Gouzerh F, Buatois B, Hervé M, Mancini M, Maraver A, Dormont L, Thomas F, Ganem G Odours of cancerous mouse congeners: detection and attractiveness. Biol Open. 2022;11(4):bio059208. doi:10.1242/bio.059208
Müller A-K, Köhler U, Trzebanski S, Vinik Y, Raj H, Girault J-A, Ben-Chetrit N, Maraver A, Jung S, Lev S Mouse Modeling Dissecting Macrophage-Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis. Adv Sci (Weinh). 2022;9(9):e2105696. doi:10.1002/advs.202105696
Baldacci S, Besse B, Avrillon V, Mennecier B, Dubray-Longeras P, Cortot A, Descourt R, Doubre H, Quantin X, Monnet I, Moro-Sibilot D, Cadranel J, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022;166. doi:10.1016/j.ejca.2022.01.018
Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste J, Garassino M, Hui R, Quantin X, Rimner A, Wu Y-L, Özgüro?lu M, Lee K, Kato T, de Wit M, Kurata T, Reck M, Cho B, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia S Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311. doi:10.1200/JCO.21.01308
Chiavarina B, Ronca R, Otaka Y, Sutton R, Rezzola S, Yokobori T, Chiodelli P, Souche R, Pourquier D, Maraver A, Faa G, Khellaf L, Turtoi E, Oyama T, Bellahcène A, Detry O, Delvenne P, Castronovo V, Nishiyama M, Turtoi A Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene. 2022;41(10):1410-1420. doi:10.1038/s41388-021-02171-z
Peters S, Pujol J-L, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba J, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel R, De Ruysscher D Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol. 2022;33(1):67-79. doi:10.1016/j.annonc.2021.09.011
Naidoo J, Vansteenkiste J, Faivre-Finn C, Özgüro?lu M, Murakami S, Hui R, Quantin X, Broadhurst H, Newton M, Thiyagarajah P, Antonia S Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer. 2022;166. doi:10.1016/j.lungcan.2022.02.003
Thomas Q, Basse C, Belaroussi Y, Beaucaire-Danel S, Daniel C, Quantin X, Girard N Brief Report on Teleconsultation in Lung Cancer: Toward a Semiotic Paradigm Shift?. JTO Clin Res Rep. 2022;3(6):100333. doi:10.1016/j.jtocrr.2022.100333
Rivet V, Quantin X, Faillie J, Lesage C, Meunier L, Faure S, Hillaire-Buys D, Lesouder C, Fabre S, Assenat E, Rullier P, Guilpain P, Maria A [Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting " ToxImmun " in Eastern Occitania]. Rev Med Interne. 2021;42(5):310-319. doi:10.1016/j.revmed.2021.01.002
Girard N, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort. Lung Cancer. 2021;162. doi:10.1016/j.lungcan.2021.10.017
Xiong H, Mancini M, Gobert M, Shen S, Furtado G, Lira S, Parkhurst C, Brengues M, Tadokoro C, Trimarchi T, Singh A, Khiabanian H, Minuzzo S, Indraccolo S, Lobry C, Aifantis I, Herranz D, Lafaille J, Maraver A Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021;11(4):1594-1608. doi:10.7150/thno.48067
Basse C, Botticella A, Molina T, Falcoz P, Oulkhouir Y, Kerjouan M, Pichon E, Westeel V, Thiberville L, Quantin X, Clément-Duchêne C, Khalifa J, Tinier F, Ginoux M, Thillays F, Mordant P, Besse B, Thomas P, Péchoux C, Girard N RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection. Clin Lung Cancer. 2021;22(5):469-472. doi:10.1016/j.cllc.2021.01.020
Matheux A, Gassiot M, Fromont G, Leenhardt F, Boulahtouf A, Fabbrizio E, Marchive C, Garcin A, Agherbi H, Evrard A, Houédé N, Balaguer P, Gongora C, Mbatchi L, Pourquier P PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1. Cancers (Basel). 2021;13(14):3635. doi:10.3390/cancers13143635
Sinoquet L, Jacot W, Gauthier L, Viala M, Cayrefourcq L, Quantin X, Alix-Panabières C Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. Clin Chem. 2021;67(11):1503-1512. doi:10.1093/clinchem/hvab131
Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer. 2021;9(7):e002242. doi:10.1136/jitc-2020-002242
Chiavarina B, Costanza B, Ronca R, Blomme A, Rezzola S, Chiodelli P, Giguelay A, Belthier G, Doumont G, Van Simaeys G, Lacroix S, Yokobori T, Erkhem-Ochir B, Balaguer P, Fabbrizio E, Di Valentin E, Detry O, Jerusalem G, Goldman S, Delvenne P, Bellahcène A, Pannequin J, Castronovo V, Turtoi A Metastatic colorectal cancer cells maintain the TGF? program and use TGFBI to fuel angiogenesis. Theranostics. 2021;11(4):1626-1640. doi:10.7150/thno.51507
Kantar D, Mur E, Mancini M, Slaninova V, Salah Y, Costa L, Forest E, Lassus P, Géminard C, Boissière-Michot F, Orsetti B, Theillet C, Colinge J, Benistant C, Maraver A, Heron-Milhavet L, Djiane A MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis. Sci Rep. 2021;11(1):5752. doi:10.1038/s41598-021-85056-1
Pujol J-L, Thomas P-A, Giraud P, Denis M, Tretarre B, Roch B Lung Cancer in France. J Thorac Oncol. 2021;16(1):21-29. doi:10.1016/j.jtho.2020.09.012
Mancini M, Thomas Q-D, Bourdel S, Papon L, Bousquet E, Jalta P, La Monica S, Travert C, Alfieri R, Quantin X, Cañamero M, Maraver A Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. Cancers. 2021;13(14):3441. doi:10.3390/cancers13143441
Vendrell J, Quantin X, Aussel A, Solassol I, Serre I, Solassol J EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Transl Lung Cancer Res. 2021;10(11):4084-4094. doi:10.21037/tlcr-21-679
Thomas Q, Sinoquet L, Maraver A, Quantin X Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report. Clin Case Rep. 2021;9(5). doi:10.1002/ccr3.3973
Wislez M, Domblides C, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano J, Ricordel C, Fraisse P, Janicot H, Audigier-Valette C, Amour E, Langlais A, Rabbe N, Makinson A, Cadranel J, Laurent-Puig P, Blons H Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer. 2021;157. doi:10.1016/j.lungcan.2021.05.013
Garrido P, Pujol J-L, Kim E, Lee J, Tsuboi M, Gómez-Rueda A, Benito A, Moreno N, Gorospe L, Dong T, Blin C, Rodrik-Outmezguine V, Passos V, Mok T Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncol. 2021;17(12):1459-1472. doi:10.2217/fon-2020-1098
Institut de Recherche en Cancérologie de
